GILEAD SCIENCES, INC.
•CIK: 882095•Filing: Q4 2025
**GILEAD SCIENCES, INC.** manages a $1.9B AUM across a concentrated portfolio of six holdings. The strategy is heavily weighted toward key biopharma assets, with RCUS representing the largest allocation at $748.9M. Significant exposure is maintained in GLPG ($550.6M) and ACLX ($438.2M), indicating a focus on specialized therapeutic areas. This top-down approach suggests conviction in established drug development pipelines.
Total AUM
$1.9B
QoQ Performance
+8.0%
Positions
6
Top 10 Concentration
100.0%
Latest Filing
Q4 2025
Top Holdings Allocation
RCUS
GLPG
ACLX
ASMB
RCUS38.7%
GLPG28.4%
ACLX22.6%
ASMB7.9%
KYTX2.0%
XILIO0.3%
📈 Biggest Buys
No new positions or increases this quarter
📉 Biggest Sells
No reductions this quarter
Sector Breakdown
Other100.0%
🚪 Exited Positionssold since Q3 2025
Historical Filings
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024